[1]黄静,史学,马晓莉,等.扶正健脾方减轻Ⅲ、Ⅳ期神经母细胞瘤患儿化疗不良反应的临床观察[J].西部中医药,2020,33(03):87-89.[doi:10.12174/j.issn.1004-6852.2020.03.24]
 HUANG Jing,SHI Xue,MA Xiaoli,et al.Clinical Observation on Treating Chemotherapy-induced Adverse Reactionin Children with Stage III and IV Neuroblastoma by TCM[J].Western Journal of Traditional Chinese Medicine,2020,33(03):87-89.[doi:10.12174/j.issn.1004-6852.2020.03.24]
点击复制

扶正健脾方减轻Ⅲ、Ⅳ期神经母细胞瘤患儿化疗不良反应的临床观察
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年03期
页码:
87-89
栏目:
报道·临证经验
出版日期:
2020-03-15

文章信息/Info

Title:
Clinical Observation on Treating Chemotherapy-induced Adverse Reactionin Children with Stage III and IV Neuroblastoma by TCM
文章编号:
1004-6852(2020)03-0087-03
作者:
黄静史学马晓莉刘畅赵文
国家儿童医学中心/首都医科大学附属北京儿童医院,北京 100045
Author(s):
HUANG Jing SHI Xue△ MA Xiaoli LIU Chang ZHAO Wen
National Center for Children's Health, Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China
关键词:
神经母细胞瘤化疗扶正健脾方儿童
Keywords:
neuroblastoma chemotherapy body resistance-strengthening spleen-invigorating prescription children
分类号:
R729
DOI:
10.12174/j.issn.1004-6852.2020.03.24
摘要:
目的:观察扶正健脾方减轻Ⅲ、Ⅳ期儿童神经母细胞瘤化疗不良反应的临床效果。方法:采用前瞻性设计,将神经母细胞瘤患儿100例随机分为观察组和对照组各50例。对照组单纯采用化疗,观察组在化疗基础上口服扶正健脾方;3个月后评估相关情况。结果:观察组化疗不良反应(主要为骨髓抑制及消化道反应)低于对照组,化疗完成情况(包括住院天数、化疗延期天数)优于对照组,且化疗期间辅助用药情况(主要为应用粒细胞集落刺激因子及输注悬浮红细胞情况)优于对照组,差异均有统计学意义(P<0.05)。结论:扶正健脾方能降低Ⅲ、Ⅳ期神经母细胞瘤患儿化疗不良反应,减少化疗辅助用药,有助于化疗顺利完成。
Abstract:
Objective: To observe clinical effects of body resistance-strengthening spleen-invigorating prescription in the treatment of chemotherapy-induced adverse reaction in children with stage III and IV neuroblastoma. Methods: By conducting the prospective cohort study, the children were randomized into the observation group and the control group, 50 cases each group. The control group accepted chemotherapy, and the observation group took body resistance-strengthening spleen-invigorating prescription on the foundation of chemotherapy; to assess the related conditions in three months. Results: The observation group was lower than the control group in chemotherapyinduced adverse reactions (mainly bone marrow suppression and gastrointestinal reaction), superior to the control group in the completion of chemotherapy (including hospitalization days and delay days of chemotherapy), in the conditions of adjuvant drugs during the chemotherapy period (mainly the application of granulocyte colony-stimulating factor G-CSF and the infusion of suspended red blood cells) and the difference showed statistical meaning(P<0.05). Conclusion: Body resistance-strengthening spleen-invigorating prescription could reducechemotherapy-induced adverse reaction in children with stage III and IV neuroblastoma, reduce chemotherapy adjuvant medication and it is helpful to finish the chemotherapy smoothly.

相似文献/References:

[1]周俭,葛信国,陈晓霞,等.益气通络方防治奥沙利铂神经毒性的临床观察[J].西部中医药,2011,24(11):25.
[2]李晶,刘小军,赵达△.康莱特软胶囊联合化疗治疗晚期卵巢癌的临床研究[J].西部中医药,2013,26(01):1.
 LI Jing,LIU Xiaojun,ZHAO Da.Clinical Study on KangLaiTe Soft Capsule and Chemotherapy in Treating Ovarian Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(03):1.
[3]王凤清,刘艳春.艾迪注射液联合CAG方案治疗老年急性髓细胞白血病40例疗效观察[J].西部中医药,2012,25(12):85.
 WANG Feng-qing,LIU Yan-chun.Observation on AiDi Injection and CAG Plan in Treating 40 Cases of Senile Acute Myelocytic Leukemia[J].Western Journal of Traditional Chinese Medicine,2012,25(03):85.
[4]高运来.贞芪扶正颗粒配合手术治疗颌面部肿瘤40例临床观察[J].西部中医药,2013,26(03):4.
 GAO Yunlai.Clinical Observation on Surgery and ZhenQi FuZheng Granules in Treating 40 Cases of Maxillo-facial Tumor[J].Western Journal of Traditional Chinese Medicine,2013,26(03):4.
[5]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
 AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(03):7.
[6]王海明,崔艺馨,王琛.四磨汤口服液对胃癌术后辅助化疗胃肠道反应的影响[J].西部中医药,2014,27(06):84.
 WANG Haiming,CUI Yixin,WANG Chen.Influence of SiMoTang Oral Liquid on Gastrointestinal Responses of the Patients with Adjuvant Chemotherapy after the Surgery of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2014,27(03):84.
[7]沈世银,周维华,陈丽萍,等.白介素-11联合循证护理对血液病化疗患者口腔黏膜炎疗效的影响[J].西部中医药,2014,27(06):126.
 SHEN Shiyin,ZHOU Weihua,CHEN Liping,et al.Influence of IL-11 and Evidence-based Nursing on Clinical Effects of Oral Mucositis of Blood Disease Patients Undergoing Chemotherapy[J].Western Journal of Traditional Chinese Medicine,2014,27(03):126.
[8]席彩霞,杨国泉,苏安平,等.贞芪益气胶囊联合 GP 方案治疗晚期非小细胞肺癌的临床研究[J].西部中医药,2014,27(09):4.
[9]张芳,孟宪明.培土生金法对气虚痰湿型肺癌化疗减毒增效的临床研究[J].西部中医药,2014,27(10):94.
[10]朱娜,代瑞花,米学丽.护理干预对妇科恶性肿瘤术后化疗患者心理控制源倾向的影响[J].西部中医药,2014,27(10):135.

备注/Memo

备注/Memo:
收稿日期:2019-02-02*基金项目:北京市中医药科技发展资金项目(JJ2015-27)。作者简介:黄静(1978—),女,博士学位,副主任医师。研究方向:实体瘤的中医辅助治疗及儿童常见病、多发病的中西医结合诊疗。△通讯作者:史学(1957—),女,硕士学位,主任医师。研究方向:儿童实体瘤的中医辅助治疗。
更新日期/Last Update: 2020-03-15